Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.34 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.34 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.34 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 4/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL58638 | 0.94 | TUBB1 (0.63) | TUBB1MMP2MMP3CTSBADAM17 | |
| SCHEMBL4368415 | 0.93 | TUBB1 (0.60) | TUBB1MMP2MMP3CTSBADAM17 | |
| SCHEMBL16176517 | 0.88 | TUBB1 (0.58) | TUBB1MMP2MMP3MMP1MMP8 | |
| SCHEMBL20723982 | 0.88 | TUBB1 (0.58) | TUBB1MMP2MMP3MMP1MMP8 | |
| SCHEMBL19282631 | 0.88 | TUBB1 (0.58) | TUBB1MMP2MMP3MMP1MMP8 | |
| SCHEMBL16176515 | 0.88 | TUBB1 (0.58) | TUBB1MMP2MMP3MMP1MMP8 | |
| SCHEMBL16176520 | 0.88 | TUBB1 (0.58) | TUBB1MMP2MMP3MMP1MMP8 | |
| SCHEMBL6801949 | 0.87 | TUBB1 (0.62) | TUBB1MMP2MMP3MMP1 | |
| SCHEMBL6802182 | 0.87 | TUBB1 (0.64) | TUBB1MMP2MMP3MMP1ADAM17 | |
| SCHEMBL57908 | 0.85 | TUBB1 (0.69) | TUBB1MMP2MMP3MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| US-8633224-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI CO., LTD. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129407-B2 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585976-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528152-B2 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | EISAI CO., LTD. (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | EISAI CO., LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192972-B2 | Hemiasterlin derivatives and uses thereof | EISAI CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063095-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885MMP2 2548/4885MMP3 4096/4885 |
| US-20080108820-A1 | Hemiasterlin Derivatives and Uses Thereof | DHCR7, HSD17B7, HCCS | TUBB1 1668/4885MMP2 3272/4885MMP3 4496/4885 |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885MMP2 2548/4885MMP3 4096/4885 |
| US-20140309174-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885MMP2 2548/4885MMP3 4096/4885 |
| US-20080051434-A1 | synthetic analog of Hemiasterlin; anticarcinogenic agent; restenosis of blood vessels subject to traumas such as angioplasty and stenting; safe and effective, while retaining stability in biological media; exhibit low cytotoxicity to non-dividing normal cells | DHCR7, CYP46A1, NR1H2 | TUBB1 1157/4885MMP2 1161/4885MMP3 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.